Download Section

Contact Information

Product Presentation

Company Information

Supporters Overview

Back to livestream

Welcome to the virtual stand of Daiichi Sankyo Deutschland GmbH

Take a look around and feel free to contact us.

Would you also like to see the HCP relevant content? Please log in here with your DocCheck data:

You are currently viewing a placeholder content from Default. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information

Welcome to the virtual stand of Daiichi Sankyo Deutschland GmbH

Take a look around and feel free to contact us.

Would you also like to see the HCP relevant content? Please log in here with your DocCheck data:

You are currently viewing a placeholder content from Default. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information

Contact Information

To the virtual cafeteria
(wonder.me)

We are available live at the following times:

December 10, 2021:
10:00–10:15 am | 11:20–11:40 am | 12:45–2:30 pm
December 11, 2021:
10:00–10:30 am | 11:30 am–1:00 pm

Bempedoinsäure / Nilemdo / Nustendi

This area is DocCheck protected. Please log in here.

Download Section

Fachinformation
Nilemdo®

.

Fachinformation
Nustendi®

.

Clear Harmony
Zulassungsstudie Bempedoinsäure

This download is DocCheck protected. Please log in here.

Studie zur Fixed Dose
Combination Bempedoinsäure/Ezetimib

This download is DocCheck protected. Please log in here.

Nilemdo und Nustendi auf einen Blick –
Produktprofile

This download is DocCheck protected. Please log in here.

Nilemdo und Nustendi Keyvisual
mit Pflichttext

This download is DocCheck protected. Please log in here.

Firmeninformation Daiichi Sankyo Deutschland GmbH

You are currently viewing a placeholder content from Default. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information

Über Daiichi Sankyo
Daiichi Sankyo entwickelt und vermarktet innovative medikamentöse Therapien zum Beispiel im Bereich Krebs und kardiovaskuläre Erkrankungen, um den Behandlungsstandard weltweit zu verbessern. Unsere starke Entwicklungspipeline baut auf einer über einhundertjährigen Forschungsgeschichte und einer Leidenschaft für Innovation auf. 16.000 Mitarbeiter in über 20 Ländern tragen dazu bei, dass Daiichi Sankyo Patienten vielversprechende neue Medikamente anbieten kann. Weitere Informationen finden Sie unter www.daiichi-sankyo.de